pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·May 4·2 min read
save

STAT+: Pump the brakes on AI, buddy; and deposition deadlock

It's tough to write nuanced headlines, but a new study on AI in emergency rooms is getting way overhyped.

May 4, 2026·read at STAT ↗

STAT PlusNewsletterHealth Care Inc. Newsletter Pump the brakes on AI, buddy; and deposition deadlock You’re reading STAT’s Health Care Inc. newsletter Manage alerts for this article Email this article Share this article By Bob HermanMay 4, 2026 Business of Health Care Reporter Bob Herman[email protected]Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care.

He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09.

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here. Hey!

Are you going to be in Washington, D.C. on May 19? I’ll be moderating a Georgetown University panel discussion on vertical integration in health care.

Jonathan Kanter, the former top antitrust official at the Department of Justice, also will make remarks. It’s gonna be lit. Reserve a spot here.

And as always, a penny for your thoughts: [email protected].Advertisement The Elevance exec you need to know Lawsuits alleging health insurers defrauded Medicare and other government programs take forever to litigate. Maybe they’re more about the friends you make along the way. STAT+ Exclusive Story Already have an account?

Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%!

Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Artificial intelligence, Congress, drug development, government agencies, Health insurance, insurance, legal, Policy, STAT+ Submit a correction requestReprints Bob Herman Business of Health Care Reporter Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care.

He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09.

Newsletter Unpacking the business — and secretive inner workings — of the U.S. health care industry Recommended The Readout May 4, 2026 UCB to acquire maker of antibody treatments for autoimmune diseases The Readout May 1, 2026 STAT Plus: Axsome wins FDA nod for Alzheimer’s agitation Advertisement Pharmalot April 30, 2026 STAT Plus: FDA wants to exclude weight loss drugs from a compounding list The Readout April 30, 2026 STAT Plus: Five-way obesity drug is super effective — in mice Insurance April 30, 2026 STAT Plus: DOJ, Elevance spar over access to top exec in Medicare Advantage fraud case Subscriber Picks

source

Reporting by STAT.

read at STAT ↗
489 words · retrieved May 4
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
AXSOME
drugs
Obesity
topics
Obesity2ImmunologyMonoclonal Antibody

related stories

  • Aug 27New data could widen use of AstraZeneca, Amgen immune disease drugBioPharma Dive
  • Aug 20Boehringer places phase 1 study of investigational drug on hold to examine ‘safety event’Fierce Biotech
  • Aug 20Chutes & Ladders—Neumora shuffles leadership ahead of INDFierce Biotech
  • Aug 13STAT+: Eli Lilly targets booming black market for retatrutideSTAT
  • Aug 5Amgen’s MariTide stands alone after obesity cull while analysts seek more M&ABioSpace